This text provides detailed information about how drugs interact with one another when treating patients with cancer. It is intended to aid in the design of treatment studies and therapeutic monitoring for cancer patients. The initial chapters address the tools for assessing pharmacokinetics and pharmacodynamic endpoints and the advantages and disadvantages of the available approaches. The second section discusses major identified sources of interpatient variations in drug disposition in relation to anticancer drugs. The body of the work consists of individual discussions of pharmacokinetics and pharmacodynamics of commercially available drugs and drugs in approval process.